BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32915667)

  • 1.
    Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
    Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
    Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
    Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
    Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 9. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
    Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
    Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
    Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.
    Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
    Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
    [No Abstract]   [Full Text] [Related]  

  • 16. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
    Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
    Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
    Drumond-Bock AL; Bieniasz M
    Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.